Immune Checkpoint Inhibitor Therapy for Microsatellite Stable Colorectal Cancer

Overall survival may be improved with tremelimumab and durvalumab compared with best supportive care.

Immune checkpoint inhibitors have substantial activity in patients with microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). First-line use of pembrolizumab was recently shown to be superior to chemotherapy (NEJM Oncol Hematol Aug 2020). However, these agents have not shown activity in microsatellite stable (MSS) CRC.

Investigators now report results of the industry-supported, multicenter, open-label, randomized, phase II, Canadian Cancer Trials Group CO.26 Study, which compared combined immune checkpoint inhibitor therapy versus best supportive care (BSC) in 180 patients with chemotherapy-refractory metastatic MSS CRC. Patients were assigned 2:1 to receive tremelimumab (75 mg every 4 weeks for 4 treatments) plus durvalu…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Immune Checkpoint Inhibitor Therapy for Microsatellite Stable Colorectal Cancer

Topics

Reviewing Author